{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5"},{"groupId":"OG001","value":"90.0"}]}],"title":"a) Yes, I had enough time to talk to my nurse and/or doctor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.4"},{"groupId":"OG001","value":"5.0"}]}],"title":"b) Yes, but I would have liked more time to talk to my nurse and/or doctor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0"},{"groupId":"OG001","value":"3.1"}]}],"title":"c) It does not matter to me if I have time to talk to my nurse and/or doctor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.6"}]}],"title":"d) No, I did not have enough time to talk to my nurse and/or doctor"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"}]}],"title":"e) No, I did not talk to my nurse and/or doctor at all"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"1.3"}]}],"title":"Patient did not answer question"}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"160"}],"units":"Participants"}],"description":"The TASQ is a 12-item, patient-reported questionnaire measuring the impact of the mode of treatment administration (TASQ-IV for IV treatment and TASQ-SC for SC treatment) on 5 domains. In addition, 3 questions (Q.9-11) are not part of the domains. The TASQ-IV/-SC was administered at treatment Cycles 3 and 6 according to the order of treatment received per arm during the Cross-Over Period. Question 9 asked the participant, \"When you receive the IV infusion/SC injection treatment, are you able to talk to your nurse and/or doctor as much as you would like about your illness?\" There were five available response options: a) Yes, I had more than enough time to talk to my nurse and/or doctor; b) Yes, but I would have liked more time to talk to my nurse and/or doctor; c) It does not matter to me if I have time to talk to my nurse and/or doctor during my treatment; d) No, I did not have enough time to talk to my nurse and/or doctor; and e) No, I did not talk to my nurse and/or doctor at all.","groups":[{"description":"This analysis set includes all participants from Arms A and B who completed the TASQ-IV questionnaire, which was administered at the last IV treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Participants: TASQ-IV Completers"},{"description":"This analysis set includes all participants from Arms A and B who completed the TASQ-SC questionnaire, which was administered at the last SC treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"All Participants: TASQ-SC Completers"}],"paramType":"NUMBER","populationDescription":"Modified Intent-to-Treat (mITT) Population","reportingStatus":"POSTED","timeFrame":"Cycle 3 Day 1 and Cycle 6 Day 1 (each cycle is 21 days)","title":"Percentage of Participants by Their Responses to Question 9 of the TASQ-IV and TASQ-SC, Assessing Whether Participants Receiving IV and SC Administration Have as Much Time as They Would Like to Talk to Their Nurse and/or Doctor About Their Illness","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}